Trial · NCT02618343
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
NCT02618343, Not applicable, Completed, The University of Texas Health Science Center at San Antonio; results first posted 2021-03-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron. Trials, record NCT02618343. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02618343
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
- NCT number
- NCT02618343
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 51 participants, actual
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Nausea
- Interventions
- IPA, Ondansetron
- First posted
- 2015-12-01
- Last updated
- 2021-03-24
- Results first posted
- 2021-03-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Nausea Reduction by 50% by Visual Analog Scale. | Baseline and up to 10 minutes | A visual analog scale (VAS) will be utilized to determine level of nausea. The VAS scale will be utilized before enrollment, at the time of medication administration, then every 2 minutes after administration for 10 minutes. The scale is a numbered linear scale from 0-10, with 0 = no nausea and 10 = worst nausea possible |
| Secondary | Number of Subjects That Required Rescue Ondansetron | 15 minutes | We will compare the number of times that a subject required ondansetron administration after IPA administration, and the number of times ondansetron repeat dose is required in the control group. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to Nausea Reduction by 50% by Visual Analog Scale. | Baseline and up to 10 minutes | Minutes | MEAN | |
| SECONDARY | Number of Subjects That Required Rescue Ondansetron | 15 minutes | EMS Patients | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Nausea Reduction by 50% by Visual Analog Scale. | Isopropyl Alcohol | 4.3 | Standard Deviation 3.1 | Minutes | |
| Time to Nausea Reduction by 50% by Visual Analog Scale. | Ondansetron Group | 3.5 | Standard Deviation 2.9 | Minutes | |
| Number of Subjects That Required Rescue Ondansetron | Isopropyl Alcohol | 0 | Participants | ||
| Number of Subjects That Required Rescue Ondansetron | Ondansetron Group | 2 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Isopropyl Alcohol | 28 | |
| Overall Study | STARTED | Ondansetron Group | 23 | |
| Overall Study | COMPLETED | Isopropyl Alcohol | 28 | |
| Overall Study | COMPLETED | Ondansetron Group | 23 | |
| Overall Study | NOT COMPLETED | Isopropyl Alcohol | 0 | |
| Overall Study | NOT COMPLETED | Ondansetron Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Isopropyl Alcohol | 0 | 28 |
| Total, all-cause mortality | Ondansetron Group | 0 | 23 |
| Total, other adverse events | Isopropyl Alcohol | 0 | 28 |
| Total, other adverse events | Ondansetron Group | 0 | 23 |
| Total, serious adverse events | Isopropyl Alcohol | 0 | 28 |
| Total, serious adverse events | Ondansetron Group | 0 | 23 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Isopropyl Alcohol vs Ondansetron Group: deaths from any cause | Trial comparisons |
| Isopropyl Alcohol vs Ondansetron Group: Number of Subjects That Required Rescue Ondansetron | Trial comparisons |
| Isopropyl Alcohol vs Ondansetron Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02618343
GET https://conductscience.org/api/trials/v1/NCT02618343/registered